Study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

Study identifier:D0510C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose, and a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Volunteers

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3043

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Sept 2009

Primary Completion Date: -

Study Completion Date: 01 Dec 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

STOCKHOLM, Sweden

Arms	Assigned Interventions
Experimental: 1 Intravenous solution given as a single ascending bolus dose	Drug: AZD3043 Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
Experimental: 2 Intravenous solution given as a single ascending bolus dose followed by a single infusion	Drug: AZD3043 Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1648&filename=CSR-D0510C00002.pdf
Download
CSR-D0510C00002.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

Astrazeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Johan Wemer

AstraZeneca